Skip to main content

Drug Interactions between alfuzosin and Qelbree

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

alfuzosin viloxazine

Applies to: alfuzosin and Qelbree (viloxazine)

MONITOR: Coadministration with viloxazine may increase the plasma concentrations of drugs that are substrates of CYP450 3A4 and/or CYP450 2D6 leading to increased toxicity. The proposed mechanism is decreased clearance due to viloxazine-mediated inhibition of CYP450 3A4 and/or CYP450 2D6. The product labeling describes viloxazine as a weak inhibitor of CYP450 3A4 and CYP450 2D6.

MANAGEMENT: Caution is advised if viloxazine is used concomitantly with drugs that are substrates of CYP450 3A4 and/or CYP450 2D6, particularly those with a narrow therapeutic range. Monitor for adverse reactions of the CYP450 3A4 or CYP450 2D6 substrate and adjust dosages as needed.

References (1)
  1. (2021) "Product Information. Qelbree (viloxazine)." Supernus Pharmaceuticals Inc

Drug and food interactions

Moderate

alfuzosin food

Applies to: alfuzosin

ADJUST DOSING INTERVAL: Administration of alfuzosin with food enhances oral bioavailability. According to the manufacturer, extent of absorption is 50% higher when administered under fed conditions compared to fasting conditions.

MANAGEMENT: To ensure maximal oral absorption, alfuzosin should be administered with or immediately after a meal.

References (1)
  1. (2003) "Product Information. Uroxatral (alfuzosin)." sanofi-aventis

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer